NCT07033013RecruitingNot Applicable
A Randomized, Double Blind, Placebo Controlled, Clinical Study to Examine the Benefits of an Oral Product in Panelists With Menopausal Symptoms Including Vasomotor Symptoms (VMS).
Olly, PBC1 site in 1 country40 target enrollmentStarted: July 7, 2025Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- 24 hour effects following single dose of Mellow Menopause - Hot Flashes
Study Overview
Brief Summary
Randomized, Double-Blind, Placebo-Controlled, Single-Center Clinical Study with a Run-in Baseline, Daily Diary Log, and Validated Questionnaires (Greene GCS) with Oral Dietary Supplement
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Supportive Care
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 40 Years to 65 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy Females aged 40 to 65 years
- •Self-reporting menopausal symptoms (> 5 hot flashes per day) and have been present for a minimum of previous 60 days prior to baseline visit
- •Reporting a variable cycle length of > 7 days different from normal
- •NORMAL BMI (per metropolitan life tables): under 30 kg/m2
- •Able to read, understand, and complete the study questionnaire and records.
- •Able to understand the study procedures.
- •Able to comply with all study requirements.
- •Written informed consent to participate in the study.
- •Willingness to actively participate in the study and to come to the scheduled visits.
Exclusion Criteria
- •Pregnancy or breastfeeding.
- •Immune insufficiency
- •Women of childbearing potential including those still having a menstrual cycle on a regular basis who are not perimenopausal, menopausal or post-menopausal.
- •History of hysterectomy
- •Women on hormone replacement therapy
- •Use of systemic corticosteroids or immunosuppressant drugs.
- •Other diseases or medications that might directly interfere in the study or put the panelist's health under risk, such as: thyroid disease, diabetes mellitus, history of hormone dependent (gynecological) cancer, endometrial hyperplasia, uterine cancer, endometrial cancer, drug and alcohol abuse, mental disorder, abnormality in renal and liver functions, personal or family history of breast cancer in a first degree relative, and history of clotting disorder such as deep vein thrombosis.)
- •Cardiovascular, chronic liver, thyroid or kidney diseases; a history of cancer; a disease or condition that could influence the participants' ability to follow the study protocol
- •Alcohol or drug abuse
- •Use of hormonal contraceptives within the last 3 months
- •Use of other menopause supplements or drugs
- •Uncontrolled hypertension (160/100 mmHg or higher, measured after 10 min of seated rest)
- •Oophorectomy or amenorrhea > two years.
- •Participating in a different clinical trial within one month of the start of this clinical trial or planning to participate in another clinical trial during the trial period
- •Continuous intake of foods based on Cynanchum wilfordii Hemsley, Phlomis umbrosa Turczaninow, and Angelica gigas Nakai within the past month
- •Employees of the institute or the brand owner or the manufacturers of the product
- •Note: Habitual medicine and supplement intake will be registered prior to inclusion in the study
Arms & Interventions
Placebo
Placebo Comparator
Instructions: Take 1 capsule when having a hot flash at the onset of a hot flash (not to exceed 1 capsule/day). Only treat 1 hot flash during a 24-hour period.
Intervention: Placebo (Dietary Supplement)
Dietary Supplement with actives
Active Comparator
Instructions: Take 1 capsule when having a hot flash at the onset of a hot flash (not to exceed 1 capsule/day). Only treat 1 hot flash during a 24-hour period.
Intervention: Dietary Supplement with actives (Dietary Supplement)
Outcomes
Primary Outcomes
24 hour effects following single dose of Mellow Menopause - Hot Flashes
Time Frame: From baseline Day 7 to Treatement Day 1 (Day 8 of study)
To assess the efficacy for improvement of a treatment product on menopausal vasomotor symptoms (hot flashes- intensity, duration) within 24 hours compared to placebo through daily diary data and MenoLife application based diary.
Secondary Outcomes
- Improvement of overall daily menopausal vasomotor symptoms(from enrollment to end of study at Day 15)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
A double-blind, placebo-controlled, single-center, randomized, parallel-group clinical trial, the timing of early intervention with Fluticason Furoate for patients with Japanese cedar pollinosis.Japanese cedar pollinosisJPRN-UMIN000012861Department of Otorhinolaryngology, Head & Neck Surgery, Faculty of Medicine, University of Yamanashi150
Completed
Phase 4
A double-blind, placebo-controlled, single-center, randomized, parallel-group clinical trial, efficacy of early intervention with Fluticason Furoate for patients with Japanese cedar pollinosis.Japanese cedar pollinosisJPRN-UMIN000005154Department of Otorhinolaryngology, Head & Neck Surgery, Faculty of Medicine, University of Yamanashi120
Recruiting
Unknown
A single-center, double-blind, placebo-controlled, randomized, parallel-group study to evaluate the efficacy and safety of Intraarticular injections of autologous synovial stem cells for knee osteoarthritis (Investigator initiated clinical trial)Osteoarthritis of the kneeD020370JPRN-jRCT2033230017Sekiya Ichiro14
Completed
Not Applicable
A single-center, double-blind, placebo-controlled, randomized study to investigate the tolerability, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single- and multiple-dose ACT-541468 in healthy Japanese and Caucasian subjects.Sleeping disordersinsomniaNL-OMON45722Actelion Pharmaceuticals60
Completed
Phase 1
A placebo and comparator controlled phase 1, safety and tolerability study of 3 ascending doses of INP105 (intranasal OLZ by I231 POD® device).Acute Agitation in SchizophreniaAcute Agitation in Bipolar I DisorderNeurological - Other neurological disordersMental Health - SchizophreniaACTRN12618000966291Clinical Network Services (CNS) Pty Ltd40